invas
fungal
diseas
ifd
particularli
invas
aspergillosi
ia
infecti
complic
affect
mainli
patient
haematolog
disord
prolong
neutropenia
longterm
high
dose
corticosteroid
treatment
allogen
stem
cell
transplant
sct
ia
set
associ
high
morbid
mortal
particularli
promptli
diagnos
unfortun
diagnosi
ia
hematolog
patient
challeng
nonspecif
clinic
manifest
low
yield
fungal
cultur
difficulti
perform
invas
diagnost
procedur
due
thrombocytopenia
poor
gener
condit
addit
azol
resist
fumigatu
strain
increasingli
frequent
sever
geograph
region
given
low
rate
posit
cultur
case
risk
remain
undetect
compromis
outcom
diagnost
criteria
ifd
immunocompromis
patient
develop
eortcmsg
subsequ
revis
establish
three
level
certainti
diagnosi
proven
probabl
possibl
particular
probabl
ia
combin
host
factor
presenc
predispos
condit
plu
clinic
criterion
plu
mycolog
criterion
requir
clinic
criteria
case
pulmonari
ia
includ
one
follow
typic
radiolog
lesion
lung
comput
tomographi
ct
scan
dens
wellcircumscrib
lesion
without
halo
sign
aircresc
sign
caviti
mycolog
criteria
pulmonari
aspergillosi
detect
galactomannan
gm
serum
bronchoalveolar
lavag
fluid
bal
direct
test
posit
sputum
possibl
ia
diagnos
presenc
host
clinic
criteria
absenc
mycolog
document
although
criteria
revolution
clinic
research
epidemiolog
studi
ia
cover
numer
possibl
clinic
among
frequent
presenc
host
criteria
posit
mycolog
criteria
lung
lesion
differ
aforement
typic
one
patient
remain
unclassifi
accord
eortcmsg
criteria
usual
treat
ia
sever
studi
show
truli
fact
recent
observ
eortc
studi
classifi
ifd
exclud
thu
suitabl
consid
certain
neg
control
european
prospect
invas
mould
diseas
audit
pimda
protocol
addit
perform
gm
might
suboptim
certain
set
exampl
patient
receiv
mould
activ
agent
breakthrough
ia
suspect
molecular
method
polymeras
chain
reaction
pcr
abl
detect
aspergillu
dna
bal
sampl
good
sensit
specif
although
recent
year
mani
focus
diagnost
role
aspergillu
pcr
use
yet
recommend
updat
idsa
guidelin
diagnosi
manag
aspergillosi
mostli
lack
standardis
valid
advantag
includ
possibl
detect
fungal
dna
also
longer
viabl
antifung
treatment
start
confirm
presenc
aspergillu
higher
sensit
cultur
similarli
gm
addit
certain
molecular
method
offer
possibl
detect
resist
mutat
aspergillu
fumigatu
even
absenc
strain
growth
aim
studi
evalu
perform
commerci
avail
aspergillu
fumigatu
realtim
quantit
pcr
qpcr
alon
combin
gm
bal
sampl
form
patient
high
risk
ia
variou
radiolog
lesion
includ
receiv
mould
activ
antifung
addit
rate
mutat
confer
azol
resist
high
risk
patient
center
also
evalu
studi
conduct
ospedal
policlinico
san
martino
tertiari
care
center
genoa
itali
activ
allogen
sct
center
retrospect
identifi
avail
bal
sampl
year
patient
sct
andor
haematolog
malign
patient
pulmonari
lesion
report
ct
scan
bal
sampl
patient
exclud
perform
within
week
patient
underw
least
two
determin
gm
plateliatm
bioradinc
bdg
assay
serum
cutoff
valu
posit
optic
densiti
index
odi
pgml
respect
accord
manufactur
recommend
bal
sampl
subject
follow
analys
cultur
bacteria
filament
fungi
mycobacteria
gm
molecular
test
pneumocystosi
mycobacterium
tuberculosi
cytomegaloviru
herp
simplex
viru
respiratori
virus
influenza
parainfluenza
respiratori
syncyti
viru
metapneumoviru
enteroviru
rhinoviru
coronaviru
bacteria
legionella
bordetella
streptococcu
pneumonia
haemophilu
influenza
chlamydia
mycoplasma
pneumonia
direct
research
hypha
antifung
suscept
test
perform
routin
bal
gm
test
sampl
centrifug
supernat
treat
accord
manufactur
instruct
residu
sampl
gm
test
store
gm
cutoff
valu
odi
consid
posit
accord
manufactur
instruct
patient
gener
data
clinic
characterist
data
underli
diseas
includ
sct
administr
mould
activ
antifung
outcom
collect
patient
gave
inform
consent
data
collect
research
purpos
hospit
admiss
bal
perform
studi
approv
local
ethic
committe
refer
number
patient
microbiolog
result
full
medic
record
review
ct
lesion
revalu
two
radiologist
ip
gc
expertis
pulmonari
fungal
infect
classifi
typic
ifd
lesion
accord
eortcmsg
revis
atyp
lesion
consid
also
mycolog
criteria
patient
stratifi
accord
eortcmsg
criteria
four
group
provenprob
ia
possibl
ia
atyp
lung
lesion
posit
mycolog
criteria
consid
atyp
ia
ia
atyp
lung
lesion
neg
mycolog
criteria
group
mutual
exclus
group
togeth
purpos
analys
evalu
qpcr
perform
carri
consid
case
patient
provenprobableposs
ia
group
provenprob
ia
group
provenprob
iaatyp
ia
atyp
lesion
mycolog
posit
group
consid
control
patient
group
perform
qpcr
evalu
separ
receiv
receiv
mould
activ
antifung
either
prophylaxi
treatment
time
bal
bal
sampl
store
subsequ
sent
institut
microbiolog
cattolica
del
sacro
cuor
rome
molecular
diagnost
method
perform
test
aspergillu
fumigatu
realtim
qpcr
assay
ademtech
pessac
franc
multiplex
commerci
avail
ceivd
mark
assay
approv
test
respiratori
sampl
detect
dna
target
rrna
multicopi
gene
specif
mutat
singl
copi
gene
dna
extract
dna
extract
kit
automag
solut
indic
isol
purif
fungal
dna
amount
microlit
store
bal
fluid
centrifug
rpm
min
remov
microlit
supernat
pellet
resuspend
microlit
tissu
lysi
buffer
microlit
use
perform
dna
extract
automag
solut
instrument
equip
magnet
particl
processor
dna
purif
kit
ademtech
sampl
elut
microlit
intern
extract
control
ad
togeth
sampl
extract
process
indic
manufactur
procedur
assay
posit
neg
pcr
control
ad
pcr
experi
kit
perform
data
fix
limit
detect
lod
monocopi
sequenc
mutat
determin
six
copi
multicopi
gene
aspergillu
rrna
gene
lod
one
copi
specif
primer
probe
verifi
manufactur
indic
highli
specif
cutoff
posit
consid
cycl
threshold
ct
perform
cutoff
ct
also
evalu
variabl
report
median
valu
rang
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
calcul
applic
report
confid
interv
ci
distribut
continu
categor
variabl
evalu
respect
mannwhitney
test
fisher
exact
test
applic
statist
analysi
perform
use
medcalc
diagnost
test
evalu
calcul
medcalc
softwar
bvba
total
bal
sampl
patient
collect
patient
data
second
bal
procedur
perform
median
day
first
one
rang
day
also
includ
studi
patient
characterist
report
tabl
briefli
male
median
age
year
rang
year
frequent
underli
diseas
acut
myeloid
leukaemia
case
bal
perform
sct
allogen
case
median
day
sct
rang
day
case
diagnost
work
presct
evalu
median
day
sct
time
bal
patient
neutropen
receiv
mould
activ
agent
ct
scan
perform
median
day
bal
accord
eortcmsg
criteria
proven
ia
diagnos
two
case
probabl
ia
possibl
overal
probabl
case
posit
gm
bal
seven
case
receiv
antifung
therapi
diagnosi
ia
made
serum
gm
median
day
bal
perform
mainli
due
suspect
failur
breakthrough
infect
among
remain
patient
without
eortcmsg
typic
lesion
posit
mycolog
result
gm
bal
case
median
odi
rang
serum
gm
one
case
consid
case
atyp
ia
seven
case
bal
cultur
posit
filament
fungi
five
aspergillu
three
flavu
one
fumigatu
one
niger
one
fusarium
spp
one
paecilomyc
spp
patient
grow
aspergillu
diagnos
provenprob
ia
four
case
atyp
ia
one
bal
sampl
gm
posit
median
odi
rang
aspergillu
fumigatu
qpcr
posit
sampl
median
cycl
posit
rang
concord
typic
radiolog
lesion
gm
posit
bal
qpcr
posit
limit
shown
figur
patient
receiv
mould
activ
agent
patient
without
ongo
therapi
also
irrespect
radiolog
lesion
poor
concord
bal
gm
qpcr
even
bal
cutoff
posit
appli
supplement
fig
correl
bal
gm
posit
qpcr
ct
valu
pcr
posit
bal
gm
odi
valu
data
shown
classif
ia
receiv
antifung
agent
outlin
tabl
preval
posit
neg
result
bal
gm
aspergillu
fumigatu
qpcr
four
differ
ia
diagnost
categori
divid
also
patient
receiv
mould
activ
agent
time
bal
report
supplement
tabl
perform
fumigatu
qpcr
report
tabl
sensit
ci
specif
ci
patient
provenprobableposs
ia
consid
case
respect
ci
ci
consid
case
provenprob
ia
sensit
specif
similar
also
patient
atyp
ia
consid
togeth
provenprob
ia
case
tabl
consid
influenc
antifung
treatment
sensit
qpcr
higher
receiv
mould
activ
agent
time
bal
ci
compar
receiv
antifung
ci
specif
similar
respect
ci
ci
tabl
among
patient
receiv
mould
activ
agent
nine
posit
bal
gm
qpcr
posit
seven
compar
five
among
receiv
antifung
p
case
perform
much
better
qpcr
use
togeth
gm
wors
posit
qpcr
gm
requir
sensit
valu
similar
irrespect
definit
use
case
provenprob
ia
provenprobableposs
ia
provenprobableatyp
slightli
higher
case
provenprob
ia
case
tabl
cutoff
qpcr
ct
use
sensit
lower
specif
higher
cutoff
ct
provenprob
ia
sensit
ci
specif
ci
higher
sensit
receiv
mould
activ
agent
compar
treatment
respect
ci
versu
ci
qpcr
posit
three
five
bal
sampl
cultur
growth
aspergillu
ct
flavu
respect
probabl
ia
bal
gm
odi
proven
resist
ia
treatment
bal
gm
odi
niger
probabl
ia
treatment
bal
gm
odi
case
growth
fusarium
ct
bal
gm
odi
paecilomyc
ct
bal
gm
odi
neg
one
case
flavu
bal
gm
odi
one
case
fumigatu
bal
gm
odi
overal
patient
neg
mycolog
atyp
lesion
posit
fumigatu
qpcr
eight
receiv
mould
activ
drug
bal
either
treatment
prophylaxi
includ
four
patient
start
mouldact
agent
bal
eight
patient
receiv
mould
activ
agent
within
month
bal
aliv
week
followup
thu
consid
high
mortal
ia
patient
hematolog
malign
untreat
consid
fals
posit
qpcr
colon
mutat
detect
one
case
sct
recipi
previous
expos
azol
prolong
treatment
ia
first
sct
second
sct
gm
bal
posit
cultur
neg
initi
bal
azol
therapi
start
clinic
diagnosi
treatment
failur
therapi
chang
liposom
amphotericin
b
gm
becam
neg
radiolog
lesion
improv
patient
deceas
month
transplant
due
relaps
acut
leukemia
retrospect
studi
show
poor
sensit
qpcr
fumigatu
better
result
patient
receiv
mould
activ
agent
time
bal
sensit
vs
respect
moder
specif
respect
combin
perform
qpcr
gm
significantli
better
use
qpcr
alon
cohort
includ
select
patient
high
risk
ia
variou
radiolog
lesion
bal
perform
mainli
noninvas
result
neg
ia
diagnosi
reach
test
moreov
lung
lesion
atyp
accord
eortcmsg
criteria
posit
mycolog
result
patient
unclassifi
accord
eortc
usual
consid
ia
therefor
could
includ
control
assess
diagnost
perform
howev
even
patient
includ
control
group
nontyp
lesion
neg
mycolog
belong
high
risk
popul
posit
pcr
easili
interpret
fals
posit
result
inde
patient
group
posit
pcr
receiv
empir
mould
activ
agent
remain
posit
pcr
could
confid
consid
fals
posit
result
colonis
moreov
even
presenc
altern
diagnosi
serv
criterion
absenc
ia
sinc
fungal
bacteri
viral
coinfect
frequent
good
diagnost
perform
report
metaanalys
includ
mainli
studi
inhous
method
sensit
specif
report
howev
recent
studi
sensit
markedli
lower
approxim
commerci
assay
allow
standard
high
reproduc
valid
qualiti
control
howev
contain
control
dna
extract
may
differ
hypha
free
dna
qualiti
control
bal
addit
perform
depend
assay
use
clinic
set
low
valu
obtain
studi
compar
perform
describ
date
literatur
use
howev
studi
includ
patient
high
rate
cultureposit
respiratori
sampl
inde
sensit
cohort
respiratori
sampl
posit
cultur
case
probabl
ia
posit
bal
cultur
case
fungal
rhinosinus
high
concentr
fungu
dna
also
recent
studi
compar
variou
diagnost
method
report
sensit
patient
provenprob
ia
high
rate
posit
cultur
addit
cohort
sensit
lower
hematolog
patient
intens
care
unit
icu
suggest
lower
fungal
burden
suffici
caus
ifd
highli
immunocompromis
inde
also
low
yield
fungal
cultur
rather
low
median
bal
gm
odi
confirm
low
burden
viabl
mould
studi
therefor
perform
cohort
low
fungal
burden
remain
establish
anoth
explan
low
sensit
qpcr
even
subgroup
bal
gm
posit
patient
probabl
ia
might
infect
speci
fumigatu
detect
assay
interest
factor
influenc
sensit
cohort
presenc
mould
activ
treatment
time
bal
increas
sensit
one
possibl
explan
mould
activ
agent
caus
lysi
fungal
wall
higher
percentag
free
dna
detect
respiratori
tree
particularli
supernat
centrifug
bal
sampl
part
use
avail
free
fungal
dna
would
result
much
better
sensit
dna
extract
critic
process
perform
fungal
observ
indirectli
confirm
cohort
report
higher
perform
pcr
bal
serum
receiv
mould
activ
also
studi
rate
qpcr
posit
gm
posit
bal
sampl
higher
form
patient
receiv
mould
activ
drug
compar
treat
better
specif
portion
bal
fluid
use
might
warrant
sinc
test
supernat
dna
still
within
organ
phagocyt
host
cell
might
detect
specif
qpcr
studi
lower
abovement
studi
use
howev
studi
heathi
control
patient
high
risk
ia
lung
lesion
refer
recent
prospect
eortc
studi
ia
consid
case
pcr
repres
posit
mycolog
criterion
bdg
gm
neg
half
patient
surviv
month
without
antifung
treatment
without
develop
ia
confirm
either
fals
posit
case
colon
obvious
could
establish
due
retrospect
natur
studi
pcr
result
avail
time
diagnosi
document
high
rate
clinic
irrelev
fals
posit
result
furthermor
consid
crossreact
speci
studi
qpcr
specif
fumigatu
posit
four
case
differ
speci
grew
cultur
two
flavu
bal
gm
odi
one
fusarium
spp
one
paecilomyc
although
case
fungi
aspergillu
coinfect
might
present
unlik
base
neg
bal
gm
contrari
case
crossreact
method
strain
flavu
alreadi
describ
fals
posit
result
might
particularli
like
case
high
fungal
burden
demonstr
two
case
clinic
point
view
qpcr
detect
speci
aspergilllu
sinc
speci
fumigatu
might
preval
particular
geograph
zone
exampl
flavu
although
triazoleresist
strain
fumigatu
increas
sever
geograph
region
fortun
cohort
one
patient
mutat
account
rate
among
pcr
posit
sampl
low
incid
line
report
itali
howev
consid
caution
given
overal
poor
sensit
qpcr
assay
although
molecular
method
import
tool
addit
cultur
monitor
chang
resist
patter
also
case
detect
one
resist
mutat
might
use
final
absenc
detect
mutat
exclud
antifung
resist
case
clinic
failur
sinc
variou
mutat
pattern
occur
particularli
case
previou
azol
exposur
possibl
overestim
perform
bal
gm
frequent
mycolog
criterion
cohort
acknowledg
howev
could
avoid
popul
mostli
neg
serum
gm
bdg
result
low
cultur
yield
lung
biopsi
frequent
feasibl
conclus
studi
demonstr
aspergillu
fumigatu
qpcr
bal
perform
togeth
gm
may
offer
clinic
contribut
particularli
patient
receiv
mould
activ
agent
gm
usual
neg
pcr
better
sensit
howev
assay
detect
common
speci
prefer
test
materi
supernat
might
result
higher
sensit
pcr
might
valuabl
tool
detect
antifung
resist
case
infect
colon
may
signific
implic
treatment
prophylaxi
ia
